Development, synthesis and structure-activity-relationships of inhibitors of the macrophage infectivity potentiator (Mip) proteins of Legionella pneumophila and Burkholderia pseudomallei

Bioorg Med Chem. 2016 Nov 1;24(21):5134-5147. doi: 10.1016/j.bmc.2016.08.025. Epub 2016 Aug 20.

Abstract

The bacteria Burkholderia pseudomallei and Legionella pneumophila cause severe diseases like melioidosis and Legionnaire's disease with high mortality rates despite antibiotic treatment. Due to increasing antibiotic resistances against these and other Gram-negative bacteria, alternative therapeutical strategies are in urgent demand. As a virulence factor, the macrophage infectivity potentiator (Mip) protein constitutes an attractive target. The Mip proteins of B. pseudomallei and L. pneumophila exhibit peptidyl-prolyl cis/trans isomerase (PPIase) activity and belong to the PPIase superfamily. In previous studies, the pipecolic acid moiety proved to be a valuable scaffold for inhibiting this PPIase activity. Thus, a library of pipecolic acid derivatives was established guided by structural information and computational analyses of the binding site and possible binding modes. Stability and toxicity considerations were taken into account in iterative extensions of the library. Synthesis and evaluation of the compounds in PPIase assays resulted in highly active inhibitors. The activities can be interpreted in terms of a common binding mode obtained by docking calculations.

Keywords: Burkholderia pseudomallei; Docking analysis; Legionella pneumophila; Macrophage infectivity potentiator protein; Structure–activity-relationships; Synthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Burkholderia pseudomallei / enzymology*
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Legionella pneumophila / enzymology*
  • Molecular Docking Simulation
  • Molecular Structure
  • Peptidylprolyl Isomerase / antagonists & inhibitors*
  • Peptidylprolyl Isomerase / metabolism
  • Structure-Activity Relationship

Substances

  • Enzyme Inhibitors
  • Peptidylprolyl Isomerase